FY2026 Earnings Estimate for BCAX Issued By HC Wainwright

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Analysts at HC Wainwright issued their FY2026 EPS estimates for Bicara Therapeutics in a research note issued on Friday, May 16th. HC Wainwright analyst R. Burns expects that the company will post earnings of ($2.59) per share for the year. HC Wainwright has a “Buy” rating and a $41.00 price target on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

Several other analysts have also issued reports on BCAX. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.01 price target on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Finally, Wells Fargo & Company assumed coverage on shares of Bicara Therapeutics in a research report on Thursday, April 17th. They issued an “underweight” rating and a $8.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $32.00.

Bicara Therapeutics Stock Performance

Shares of NASDAQ BCAX opened at $15.04 on Monday. The firm has a 50 day moving average of $12.88 and a 200 day moving average of $15.13. Bicara Therapeutics has a 12-month low of $8.91 and a 12-month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.28).

Hedge Funds Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of BCAX. California State Teachers Retirement System bought a new position in shares of Bicara Therapeutics during the fourth quarter worth $25,000. CWM LLC bought a new position in shares of Bicara Therapeutics during the first quarter worth $29,000. Spire Wealth Management bought a new position in shares of Bicara Therapeutics during the fourth quarter worth $31,000. BNP Paribas Financial Markets bought a new position in shares of Bicara Therapeutics during the fourth quarter worth $32,000. Finally, Legal & General Group Plc bought a new position in shares of Bicara Therapeutics during the fourth quarter worth $33,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.